The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
 
Mafalda Oliveira
Honoraria - Eisai Europe; Guardant Health; MSD; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; ITeos Therapeutics; Pierre Fabre; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Pierre Fabre; Roche
 
Erika P. Hamilton
Consulting or Advisory Role - Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Relay Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); InventisBio (Inst); Jacobio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Radius Health (Inst); Regeneron (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Jason Incorvati
Consulting or Advisory Role - 2nd.MD
 
Begoña Bermejo de la Heras
Consulting or Advisory Role - MSD; Pierre Fabre; Roche
Speakers' Bureau - AstraZeneca/MedImmune; Daiichi Sankyo; MSD; Novartis; Pfizer; Roche
 
Emiliano Calvo
Employment - HM Hospitales; START
Leadership - START
Stock and Other Ownership Interests - Oncoart Associated; START
Honoraria - HM Hospitales
Consulting or Advisory Role - Adcendo; Alkermes; Amcure; Amunix; Anaveon; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Janssen-Cilag; MedSIR; MonTa Biosciences; MSD Oncology; Nanobiotix; Nouscom; Novartis; OncoDNA; PharmaMar; PsiOxus Therapeutics; Roche/Genentech; Sanofi; Seagen; Servier; Syneos Health; T-Knife; TargImmune Therapeutics
Research Funding - Achilles Therapeutics (Inst); BeiGene; START
Other Relationship - Investigational Therapeutics in Oncological Sciences
 
Javier García-Corbacho
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - BMS
 
Manuel Ruiz-Borrego
Honoraria - AstraZeneca/MedImmune; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca/MedImmune; Novartis; Pfizer
Speakers' Bureau - AstraZeneca/MedImmune; Novartis; Pfizer
 
Christos Vaklavas
Employment - Flatiron Health (I)
Honoraria - Guidepoint Global
Consulting or Advisory Role - Daiichi Sankyo; Gilead Sciences
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Genentech (Inst); H3 Biomedicine (Inst); Incyte (Inst); Innocrin Pharma (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Seagen (Inst); TRACON Pharma (Inst); Zymeworks (Inst)
Other Relationship - Daiichi Sankyo; Puma Biotechnology; Takeda
(OPTIONAL) Uncompensated Relationships - Genentech
 
Nicholas C. Turner
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Repare Therapeutics; Roche; Taiho Pharmaceutical; Zeno pharmaceuticals
Research Funding - AstraZeneca (Inst); Bio-Rad (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)
 
Eva M. Ciruelos
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Roche
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Manish R. Patel
Leadership - ION Pharma
Honoraria - Adaptive Biotechnologies; Bayer; Genentech; Janssen Oncology; Pfizer; Pharmacyclics
Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen
Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical
Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); Artios (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); BioTheryX (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); IgM Biosciences (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kymab (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); nurix (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PubGene (Inst); Puretech (Inst); PureTech (Inst); PureTech (Inst); QiLu Pharmaceutical (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Samumed (Inst); Seven and Eight Biopharmaceuticals (Inst); Silicon Therapeutics (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TeneoBio (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Treadwell Therapeutics (Inst); Treadwell Therapeutics (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst); Zymeworks (Inst)
 
Anne C. Armstrong
Stock and Other Ownership Interests - AstraZeneca (I)
Consulting or Advisory Role - Gilead Sciences; MSD
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; MSD Oncology
 
Peter Kabos
Consulting or Advisory Role - Lilly (Inst)
Research Funding - Angiochem (Inst); AstraZeneca/MedImmune (Inst); Genentech (Inst); Lilly (Inst); Pfizer (Inst); Radias Health (Inst); Sanofi (Inst)
 
Chris Twelves
Honoraria - Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Pfizer
Speakers' Bureau - Daiichi Sankyo; Eisai; Pfizer
Travel, Accommodations, Expenses - Eisai; MSD Oncology; Pfizer
 
Tim Brier
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune (Inst)
 
Itziar Irurzun-Arana
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune (Inst)
 
Teresa Klinowska
Employment - AstraZeneca/MedImmune
Leadership - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune (Inst)
 
Justin P.O. Lindemann
Employment - AstraZeneca/MedImmune
Leadership - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune (Inst)
 
Christopher J. Morrow
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune (Inst)
 
Richard D. Baird
Consulting or Advisory Role - AstraZeneca (Inst); Daiichi Sankyo (Inst); Molecular Partners (Inst); Novartis (Inst); Roche/Genentech (Inst); Shionogi (Inst)
Research Funding - AstraZeneca (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Carrick Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Molecular Partners (Inst); Roche (Inst); Sanofi (Inst); Shionogi (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Molecular Partners; Shionogi